Am­gen trig­gers yet an­oth­er re­vamp, mov­ing re­searchers to two big hubs

Am­gen CEO Bob Brad­way

Am­gen is once again re­struc­tur­ing its op­er­a­tions with plans to re­lo­cate, re­as­sign or ax about 500 jobs at its Thou­sand Oaks, CA head­quar­ters. The moves in­clude about 100 who are be­ing re­lo­cat­ed to re­search cen­ters in Cam­bridge, MA or South San Fran­cis­co.

The R&D part of this re­vamp in­cludes staffers at Am­gen’s dis­cov­ery re­search and trans­la­tion­al sci­ences de­part­ment. And, sep­a­rate­ly, about 50 jobs will be re­lo­cat­ed to Tam­pa, where Am­gen is open­ing up a ma­jor new ca­pa­bil­i­ty cen­ter with 450 jobs.

“Just over 100 in­di­vid­u­als in Dis­cov­ery Re­search and Trans­la­tion­al Sci­ences will be im­pact­ed by or­ga­ni­za­tion­al changes,” Am­gen spokesper­son Kris­ten Davis tells me via email. “We have of­fered re­lo­ca­tion op­por­tu­ni­ties to some staff mem­bers from Thou­sand Oaks to San Fran­cis­co or Cam­bridge. Oth­ers will con­tin­ue to be em­ployed by Am­gen for vary­ing lengths of time while we make this tran­si­tion. Im­pact­ed staff el­i­gi­ble to ap­ply for roles with­in Am­gen may do so.”

She adds: “The rea­son for this move is to align and ad­vance func­tion­al ca­pa­bil­i­ties, co-lo­cate staff with cross-func­tion­al teams and in­crease ac­cess to in­no­va­tion and tal­ent in Cam­bridge and San Fran­cis­co.”

The move over­all cov­ers close to 10% of Am­gen’s Thou­sand Oaks staff. And it fol­lows close­ly on the heels of CEO Bob Brad­way’s promise to add 1,600 jobs at Am­gen this year, min­utes af­ter the pres­i­dent had fin­ished a ha­rangue about the new Amer­i­can jobs he ex­pect­ed in ex­change for re­duced reg­u­la­tions. As a spokesper­son not­ed at the time, though, Brad­way was al­so re­fer­ring to new hires to re­place em­ploy­ees lost to at­tri­tion.

Brad­way — who runs the com­pa­ny by strict Wall Street stan­dards — prefers to keep a tight rein on head count at the phar­ma gi­ant. Back in 2014 the com­pa­ny launched a com­pa­ny-wide re­struc­tur­ing that claimed about 20% of its to­tal staff, in­clud­ing a re­search cen­ter in Seat­tle. He fol­lowed up in 2015, ax­ing 300 of the 750 staffers picked up in the $10 bil­lion Onyx buy­out, clos­ing the cam­pus, which is now part of the Google em­pire.

Am­gen is al­so close­ly fol­low­ing a big trend in phar­ma, con­cen­trat­ing R&D in the two big hubs on the East and West Coasts while ratch­et­ing down op­er­a­tions scat­tered out­side the pri­ma­ry bio­phar­ma re­gions. Mer­ck has been do­ing that most re­cent­ly as well.

Biotech and Big Phar­ma: A blue­print for a suc­cess­ful part­ner­ship

Strategic partnerships have long been an important contributor to how drugs are discovered and developed. For decades, big pharma companies have been forming alliances with biotech innovators to increase R&D productivity, expand geographical reach and better manage late-stage commercialization costs.

Noël Brown, Managing Director and Head of Biotechnology Investment Banking, and Greg Wiederrecht, Ph.D., Managing Director in the Global Healthcare Investment Banking Group at RBC Capital Markets, are no strangers to the importance of these tie-ups. Noël has over 20 years of investment banking experience in the industry. Before moving to the banking world in 2015, Greg was the Vice President and Head of External Scientific Affairs (ESA) at Merck, where he was responsible for the scientific assessment of strategic partnership opportunities worldwide.

Credit: Shutterstock

How Chi­na turned the ta­bles on bio­phar­ma's glob­al deal­mak­ing

Fenlai Tan still gets chills thinking about the darkest day of his life.

Three out of eight lung cancer patients who received a tyrosine kinase inhibitor developed by his company, Betta Pharma, died in the span of a month. Tan, the chief medical officer, was summoned to Peking Union Medical College Hospital, where the head of the clinical trial department told him that the trial investigators would be conducting an autopsy to see if the patients had died of the disease — they were all very sick by the time they enrolled — or of interstitial lung disease, a deadly side effect tied to the TKI class that’s been reported in Japan.

No­var­tis' sec­ond at­tempt to repli­cate a stun­ning can­cer re­sult falls flat

Novartis’ hopes of turning one of the most surprising trial data points of the last decade into a lung cancer drug has taken another setback.

The Swiss pharma announced Monday that its IL-1 inhibitor canakinumab did not significantly extend the lives or slow the disease progression of patients with previously untreated locally advanced or metastatic non-small cell lung cancer when compared to standard of-care alone.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis dumps AveX­is pro­gram for Rett syn­drome af­ter fail­ing re­peat round of pre­clin­i­cal test­ing

Say goodbye to AVXS-201.

The Rett syndrome gene therapy drug made by AveXis — the biotech that was bought, kept separate, then renamed and finally absorbed by Novartis into its R&D division — has been dropped by the biopharma.

In Novartis’ third quarter financial report, the pharma had found that preclinical data did not support development of the gene therapy into IND-enabling trials and beyond. The announcement comes a year after Novartis told the Rett Society how excited it was by the drug — and its potential benefits and uses.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

Peter Nell, Mammoth Biosciences CBO

UP­DAT­ED: Jen­nifer Doud­na spin­out inks a Mam­moth CRISPR deal with Ver­tex worth near­ly $700M

When a company gets its start in gene editing pioneer Jennifer Doudna’s lab, it’s bound to make headlines. But three years in, the fanfare still hasn’t died down for Mammoth Biosciences. Now, the Brisbane, CA-based company is cheering on its first major R&D pact.

Mammoth unveiled a nearly $700 million deal with Vertex on Tuesday morning, good for the development of in vivo gene therapies for two mystery diseases. The stars of the show are Mammoth’s ultra-small CRISPR systems, including two Cas enzymes licensed from Doudna’s lab over the past couple years, Cas14 and Casɸ.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

AstraZeneca CEO Pascal Soriot (Raphael Lafargue/Abaca/Sipa USA)

A com­bo of As­traZeneca's Imfinzi and chemo wins where oth­ers have failed in piv­otal bil­iary tract test

Looking to run with the big dogs in the PD-(L)1 class, AstraZeneca’s Imfinzi has a tall hill to climb to compete in an increasingly bustling market. An aggressive combo strategy for the drug has paid off so far, and now AstraZeneca is adding another notch to its belt.

A combo of Imfinzi (durvalumab) and chemotherapy significantly extended the lives of first-line patients with advanced biliary tract cancer over chemo alone, according to topline results from the Phase III TOPAZ-1 study revealed Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

Sean Ianchulev, Eyenovia CEO and CMO

Re­cent court de­ci­sion push­es FDA to re­ject and re­clas­si­fy drug-de­vice com­bo, crush­ing shares

Back in April, the FDA lost a crucial court case in which its broad discretion of regulating medical products that might satisfy the legal definitions of either “drug” and/or “medical device” was sharply curtailed.

In addition to the appeals court ruling that Genus Medical Technologies’ contrast agent barium sulfate (aka Vanilla SilQ) should not be considered a drug, as the FDA had initially ruled, but as a medical device, the agency also was forced to spell out which drugs would transition to devices as a result of the ruling.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

An­gion's or­gan dam­age drug strikes out again, this time in high-risk kid­ney trans­plant pa­tients

After flopping a test in Covid-19 earlier this year, Angion’s lead organ damage drug has now hit the skids again in kidney transplant patients.

Angion and partner Vifor Pharma’s ANG-3777 failed to beat out placebo in terms of improving eGFR, a measure of kidney function, in patients who had received a deceased donor kidney transplant and were at high risk of developing what is known as delayed graft function, according to Phase III results released Tuesday.

(Photo courtesy Pfizer)

FDA's vac­cine ad­comm votes al­most unan­i­mous­ly in fa­vor of Pfiz­er's Covid-19 vac­cine for younger chil­dren

The FDA’s Vaccines and Related Biological Products Advisory Committee on Tuesday voted 17-0, with one panelist abstaining, that the benefits of the Pfizer-BioNTech Covid-19 vaccine outweigh the risks for children between the ages of five and 12.

The vote will likely trigger a process that could allow the shots to begin rolling out as early as next week.

The vaccine, which is one-third of the adult Pfizer dose, proved to be about 90% effective in a placebo-controlled trial in which about 1,500 kids in this age range received the vaccine, and only about 12% of those receiving the vaccine had any adverse event. All serious adverse events in the trial were unrelated to the vaccine.